Get the knowledge

You’re Still Cycling. So Why Do You Feel Like You’re Falling Apart?

Your periods still come. Your GP ran blood tests and called them normal. You’ve been offered antidepressants, or told it’s stress, or — if you’re lucky — offered HRT. And yet: the rage that comes from nowhere in the second half of your cycle. The flooding. Breasts so tender you can’t sleep on your side. Two weeks of feeling relatively sane, followed by two weeks of barely recognising yourself.

This is not depression. It is not anxiety in the psychiatric sense. It is not “just stress.”

This is early perimenopause — specifically, The Progesterone Shift — and it has a precise biological mechanism that most standard medicine misses entirely, because the blood tests look normal and the narrative is still “wait until your periods stop.”

You are not losing oestrogen yet. You are losing progesterone — and the imbalance that creates is one of the most disruptive hormonal experiences of a woman’s life. Understanding the mechanism doesn’t just validate what you’re living through. It gives you a map.

(This page is part two of the perimenopause series. If you haven’t read What Early Perimenopause Actually Is, start there.)

What Is Actually Happening: The Two-Phase Context

Perimenopause is not a single event. It has two distinct phases, governed by two different hormonal stories.

Late perimenopause — the phase most people know about — is the oestrogen withdrawal phase. Hot flushes, night sweats, vaginal dryness, cognitive fog. This is what the standard menopause narrative describes.

Early perimenopause — which can begin in your late 30s or early 40s, often while periods are still regular — is something different. The driving force is not oestrogen falling. It is progesterone crashing, while oestrogen remains high or wildly fluctuating. The ratio between these two hormones becomes severely disrupted, and the symptoms that result are their own distinct constellation: flooding, rage, anxiety, breast tenderness, bloating, migraines, and 3am waking.

The biological sequence begins in the ovaries and cascades through the brain, gut, liver, stress system, and metabolic pathways simultaneously. Here is exactly how.

The Root Cause Mechanism

The “Running Out of Eggs” Narrative Is Incomplete

Before explaining the mechanism, it is worth challenging a deeply embedded misconception — because it is one of the reasons early perimenopause is so poorly understood and so poorly treated.

The standard story goes: women have a fixed egg supply, it runs out, periods stop, menopause happens. Simple countdown.

That story is not entirely true — and recent, landmark research has fundamentally rewritten it.

When a woman reaches menopause, her ovaries still contain thousands of remaining immature follicles. They do not simply disappear. What happens is something more precise, and more consequential: the environment surrounding those follicles degrades. The eggs become trapped and unresponsive — not because they are gone, but because the tissue around them has collapsed.

As leading reproductive researchers now frame it: “Ovarian aging is not just about the egg cells, but about their whole ecosystem.”

The proof came from anti-fibrotic trials. When scientists administered anti-fibrotic medications (pirfenidone) or metabolic therapies (metformin) to aged mice, they did not supply new eggs. They simply dissolved the stiff collagen and restored the local environment. The result: dormant, trapped eggs woke up, responded to hormonal signals, and successfully ovulated — effectively extending the reproductive lifespan (Morimoto et al., Science Advances, 2022).

Menopause does not happen because the ovary runs out of inventory. It happens because the warehouse becomes physically locked down. Perimenopause symptoms are not the result of an empty ovary — they are the result of hormones trying to operate within a degraded, fibrotic environment.

This reframe matters clinically. If the ecosystem is the problem, restoring the ecosystem is a legitimate therapeutic target. That is exactly what Sandra’s approach addresses.

Step 1: Follicle Depletion + Ovarian Fibrosis (the dual driver)

Every woman is born with her lifetime supply of follicles — the egg-containing structures that also produce the hormones that govern her cycle. By the early 40s, this reserve has declined substantially, and two compounding processes begin to destabilise the system.

Follicle depletion is the primary driver. Fewer follicles means the pituitary must send louder signals — raising FSH (follicle-stimulating hormone) to recruit what remains. But the remaining follicles are increasingly erratic in their response, leading to chaotic hormone production and, critically, skipped or disrupted ovulation.

Ovarian fibrosis is the compounding accelerator, and it is far less discussed than it deserves to be. Decades of monthly ovulation involve repetitive micro-trauma to the ovarian surface — each egg rupture is a wound that must heal. Over time, this cumulative tissue injury triggers chronic low-grade inflammation, a process researchers call “inflammaging.”

This inflammatory environment activates TGF-β (transforming growth factor-beta) signalling, which drives resident fibroblasts to transform into myofibroblasts — cells whose purpose is scar formation. These myofibroblasts lay down collagen, and the ovarian cortex progressively stiffens [Gu M, Yu Y, Wang Y. Ovarian fibrosis: molecular mechanisms and potential therapeutic targets. J Ovarian Res. 2024; doi:10.1186/s13048-024-01448-7]. The consequence is stark: follicles become physically compressed by their increasingly rigid surrounding tissue. They become, in effect, “deaf” to FSH signals — a process called gonadotropin desensitisation.

The pituitary, receiving poor feedback, shouts louder. FSH surges further. But the deafened follicles cannot respond reliably. The result is pronounced hormonal chaos — the wild swings of early perimenopause — rather than a smooth decline [Johnson BW, Duncan F, et al. Fibroinflammatory Signatures Increase with Age in the Human Ovary and Follicular Fluid. Int J Mol Sci. 2021;22(9):4902. doi:10.3390/ijms22094902].

Fewer follicles, plus deafer follicles, equals more chaotic hormone swings and more skipped ovulation.

Step 2: Skipped Ovulation → Progesterone Crashes

This is the pivotal moment, and it is one the standard blood test entirely misses.

Ovulation is not merely a reproductive event. It is the only significant source of progesterone in a woman’s body. When an egg is released, the follicle that housed it transforms into the corpus luteum — a temporary but powerful gland that produces progesterone throughout the second half (luteal phase) of the cycle.

When ovulation is skipped or disrupted — which happens with increasing frequency as follicle quality and quantity decline — no corpus luteum forms. No corpus luteum means no progesterone. Or severely insufficient progesterone. Or progesterone that rises briefly then collapses before the luteal phase should even have ended.

The result is progesterone decline and wild fluctuation — even while the cycle appears outwardly normal on a calendar.

Step 3: Oestrogen Dominates

With progesterone insufficient, oestrogen runs unopposed. It is critical to understand that this is a ratio problem, not necessarily a problem of absolute oestrogen excess. Oestrogen:progesterone balance matters as much as the raw numbers.

Simultaneously, the pituitary’s desperate FSH surges occasionally recruit follicles that over-respond — firing massive oestrogen spikes before crashing. This is the hormonal rollercoaster women describe: not a gentle decline, but violent peaks and troughs. High oestrogen one week. Crash the next. Progesterone never catching up.

This oestrogen dominance picture — high or spiking oestrogen relative to insufficient progesterone — is the engine that drives every symptom in early perimenopause.

Four systemic factors amplify it dramatically.

The Four Systemic Amplifiers

Amplifier 1: The Insulin-Oestrogen Loop

Blood sugar dysregulation is not merely a metabolic problem — it is a direct driver of oestrogen dominance.

High insulin (driven by a refined carbohydrate diet, sedentary patterns, or insulin resistance) stimulates the ovarian theca cells — via LH signalling — to produce excess androgens, primarily testosterone. These androgens are then converted into oestrogen via the enzyme aromatase, adding a second, insulin-driven source of oestrogen to an already oestrogen-dominant picture [Dupont J, Scaramuzzi R. Insulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycle. Biochem J. 2016;473(11):1483–501. doi:10.1042/BCJ20160124].

The loop reinforces itself: oestrogen dominance raises cortisol → cortisol raises blood glucose → blood glucose raises insulin → insulin raises theca cell androgen production → androgens aromatise to oestrogen. The cycle compounds with every refined meal and every poor night’s sleep.

Women with higher fasting insulin in early perimenopause experience more severe symptoms — not coincidentally.

Amplifier 2: Poor Oestrogen Clearance — Liver and Gut

The body has sophisticated systems for deactivating and eliminating used oestrogen. In early perimenopause, these systems are commonly overburdened, meaning oestrogen recirculates rather than being excreted.

The liver runs Phase I and Phase II detoxification pathways to neutralise oestrogen metabolites and prepare them for elimination. When liver function is compromised — by alcohol, a poor diet, high toxic load, or inadequate B vitamins and methylation nutrients — this process stalls. Oestrogen remains in active, circulating form longer than it should.

The gut — specifically the estrobolome — is where the less well-known but equally critical mechanism operates. The estrobolome is the collection of gut bacteria responsible for metabolising oestrogen. In a healthy gut microbiome, oestrogen is processed and eliminated. In a dysbiotic gut, bacteria that produce the enzyme beta-glucuronidase proliferate. Beta-glucuronidase uncouples the oestrogen that the liver has carefully packaged for disposal — essentially tearing open the exit bag — and the freed oestrogen is reabsorbed through the intestinal wall back into the bloodstream via the hepatic portal vein [Li H, Lim L, Roberts LR, et al. Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome. J Biol Chem. 2019;294(49):18586–99. doi:10.1074/jbc.RA119.010950].

The result: recycled oestrogen re-enters circulation, adding to an already dominant picture. Gut dysbiosis and constipation — which slow transit and allow more time for reabsorption — worsen this dramatically [Ma JX, Zhao L, Kang M, et al. Gut microbial beta-glucuronidase: a vital regulator in female estrogen metabolism. Gut Microbes. 2023;15(1):2236749. doi:10.1080/19490976.2023.2236749].

Amplifier 3: Xenoestrogens

Daily life exposes women to a category of compounds that the body’s hormonal measurement systems cannot detect: endocrine-disrupting chemicals (EDCs) that bind to oestrogen receptors and mimic oestrogen’s effects.

Specific plastics (including BPA and its replacements), pesticide residues on food, synthetic fragrances in personal care products and household cleaners, and certain industrial compounds all introduce foreign oestrogenic signals into the body. These compounds compound the total oestrogenic burden without contributing to oestrogen levels measurable on standard blood panels.

This matters because standard testing only measures what the body produces. It cannot see the xenoestrogen load — which means a woman with significant EDC exposure may appear to have “normal” oestrogen on a blood test while her receptors are being overwhelmed.

Amplifier 4: Chronic Stress Suppresses Progesterone via the Brain

Chronic stress is not just a mood issue. It is a direct driver of progesterone decline — but the mechanism is neurological, not biochemical theft.

You may have heard the term “pregnenolone steal” — the idea that cortisol and progesterone compete for the same raw material, and stress diverts that raw material away from progesterone production. It circulates widely online and in some popular wellness content, but it is not supported by endocrinology. The adrenal glands (which produce cortisol) and the ovaries (which produce progesterone) operate as entirely separate systems with their own substrate pools — there is no shared pipeline to steal from.

What stress actually does to progesterone is more precise, and more important to understand:

Chronic stress → elevated cortisol → cortisol signals the hypothalamus to suppress GnRH (gonadotropin-releasing hormone) → reduced LH and FSH signalling to the ovaries → follicle development is disrupted or stalled → ovulation fails to occur cleanly, or is skipped entirely → no corpus luteum forms → no progesterone is produced.

The progesterone was not stolen. Its production line was switched off by the brain.

For a woman in early perimenopause — already dealing with erratic follicle behaviour and frequent anovulatory cycles — chronic stress adds a second mechanism that suppresses ovulation. The result is deeper, more persistent progesterone decline and a more severe oestrogen dominance picture. Stress amplifies the hormonal chaos not by robbing resources, but by turning off the signal that would have produced progesterone in the first place.

The Symptoms of The Progesterone Shift

1. Heavy and Flooding Periods

No ovulation → no corpus luteum → no progesterone → oestrogen continues to thicken the endometrial lining unopposed. Progesterone’s normal role in the luteal phase is to mature and stabilise this lining, preparing it for either implantation or orderly, contained shedding. Without progesterone, the lining becomes excessively thick, structurally fragile, and unstable. When it finally sheds, it does so chaotically, heavily, and incompletely — flooding, clots, extended bleeds of 8–10 days.

The systemic amplifiers compound this significantly. Iron deficiency from previous heavy bleeds impairs platelet function, worsening clotting. The estrobolome’s oestrogen recycling sustains pelvic vasodilation. Cortisol-driven prostaglandin overproduction (PGE2) promotes local inflammation and mast cell activation. B vitamin deficiencies — B6 (a progesterone co-factor), B12 and folate (required for methylation and oestrogen clearance), B1 (required for uterine muscle contraction) — all compound the picture. Magnesium depletion impairs smooth muscle clamping. These depletions are not incidental; they are part of the same biochemical landscape.

2. Rage and Irritability

This is perhaps the most distressing symptom — not because of the anger itself, but because the woman experiencing it can see she is overreacting and still cannot stop.

Here is why: progesterone is metabolised in the brain into allopregnanolone (ALLO) — a potent positive modulator of GABA-A receptors, the brain’s primary inhibitory system. GABA is the neurological brake — the calming, moderating signal that prevents excitatory impulses from running away. When progesterone crashes, allopregnanolone levels fall sharply, and GABA-A receptor stimulation plummets [Hantsoo L, Epperson CN. Allopregnanolone in premenstrual dysphoric disorder (PMDD). Neurobiol Stress. 2020;12:100213. doi:10.1016/j.ynstr.2020.100213].

Simultaneously, unopposed oestrogen upregulates glutamate — the brain’s primary excitatory neurotransmitter — and sensitises the amygdala, the threat-detection centre. The nervous system runs excitatory-dominant. Small provocations trigger disproportionate responses. The brake is genuinely absent, not merely weak. This is neurochemistry, not character.

3. Breast Tenderness

Progesterone’s role in the luteal phase includes maturing and stabilising breast tissue — counteracting oestrogen’s proliferative drive. Oestrogen stimulates ductal proliferation and promotes fluid retention in breast lobules. Progesterone normally completes and modulates this process in the second half of the cycle.

Without progesterone, oestrogen drives continuous, unopposed ductal proliferation and fluid accumulation throughout the cycle. The oestrogen spikes of early perimenopause are often dramatically higher than those experienced in normal cycling — making this categorically different from ordinary PMS breast tenderness. The cyclical engorgement, nodularity, and tenderness that make it impossible to sleep on one’s side reflects this sustained oestrogenic stimulation without progesterone’s stabilising counterpart.

4. Bloating and Distension

Two mechanisms converge here. First, oestrogen promotes water and sodium retention via aldosterone signalling — the body holds fluid in tissues. Second, oestrogen slows gut motility. Progesterone normally offsets both of these effects: it is mildly diuretic and stimulates intestinal movement (this is why many women notice looser stools just before their period — a progesterone withdrawal effect).

Without progesterone, fluid accumulates and the gut slows simultaneously — a perfect storm for bloating, distension, and constipation. The gut dysbiosis that worsens the estrobolome also contributes directly to symptoms of digestive sluggishness and bloating, making the cycle self-reinforcing.

5. Menstrual and Hormonal Migraines

Progesterone normally stabilises oestrogen levels across the luteal phase, smoothing what would otherwise be a sharper curve. In early perimenopause, without progesterone’s moderating effect, oestrogen spikes steeply — then crashes. This rapid oestrogen withdrawal activates the trigeminovascular pathway, triggering cortical spreading depression and migraine.

The spikes are steeper. The crashes are sharper. The migraines are more frequent, more severe, and more precisely timed to the luteal phase and the onset of bleeding. Compounding this: oestrogen dominance promotes overproduction of prostaglandin PGE2, which generates neurogenic inflammation that lowers the migraine threshold further — meaning smaller triggers produce full attacks.

6. Cyclical Anxiety

The allopregnanolone pathway — the same mechanism driving rage — also explains the anxiety pattern distinctive to early perimenopause.

Allopregnanolone is the brain’s endogenous anxiolytic — its natural calming, GABA-A-modulating neurosteroid [McEvoy K, Osborne L. Allopregnanolone and reproductive psychiatry: an overview. Int Rev Psychiatry. 2019;31(3):237–44. doi:10.1080/09540261.2018.1553775]. When progesterone crashes in the luteal phase, allopregnanolone falls with it. The calming brake is removed. Chronic stress worsens this further — not by stealing progesterone precursors (a myth), but by suppressing the hypothalamic signals that would have triggered ovulation and progesterone production in the first place. Less ovulation = less progesterone = less allopregnanolone = more anxiety.

The result is anxiety that is strictly cyclical — worst in the two weeks before the period (days 14–28), when progesterone should be rising but cannot. Fine for two weeks. Unravelling for two weeks. The “I don’t know what’s wrong with me, I was fine last week” pattern is the clinical fingerprint of this mechanism. It is not generalised anxiety. It is progesterone decline expressing itself through the GABA-A system on a monthly schedule.

7. Poor Sleep and 3am Waking

Progesterone actively promotes sleep. It acts directly on GABA-A receptors (the same pathway as anxiety, the same as rage — the brain’s calming architecture) and has thermogenic effects that paradoxically support deeper sleep phases. When progesterone crashes, sleep architecture degrades: lighter sleep, more frequent waking, inability to return to sleep after 3am.

This is a critical distinction from the night sweats and thermoregulatory disruption of late perimenopause and menopause. 3am waking in early perimenopause is neurochemical, not thermoregulatory — it is GABA-A loss, not a hot flush. Women are frequently given the wrong explanation, leading to the wrong approach. Sleep hygiene tips do not restore GABA-A receptor activity.

How to Smooth the Ride

Understanding the mechanism points directly to the levers. The approach is not “add hormones and hope.” It is address the drivers — simultaneously, because they are all connected.

Slowing Fibrosis Progression

• Strength training over long endurance cardio. Prolonged cardio chronically spikes cortisol, which suppresses GnRH signalling (worsening the ovulation disruption) and suppresses MMP collagen-clearing enzymes. Progressive resistance training builds muscle — the body’s primary metabolic sink for blood glucose — directly reducing insulin resistance and the insulin-oestrogen amplification loop. It achieves this without the adrenal tax.
• Blood sugar management. Reducing refined carbohydrates and processed foods lowers fasting insulin, directly quieting the theca cell androgen-oestrogen conversion loop. It also reduces NLRP3 inflammasome activation — one of the inflammatory pathways that drives ovarian fibrosis.
• Sleep as a biological priority. Cortisol — elevated in poor sleep — suppresses matrix metalloproteinases (MMPs), the enzymes that break down and remodel collagen. Poor sleep literally accelerates fibrosis progression. This is not a lifestyle recommendation; it is mechanistic.
• Reducing EDC exposure. Switching plastic food storage to glass and stainless steel. Reviewing personal care products and household cleaners for synthetic fragrance and known endocrine disruptors. These changes reduce total oestrogenic burden in a way that cannot be replicated by any supplement.
• Stress management as progesterone protection. Cortisol-driven granulosa cell apoptosis directly depletes remaining follicle quality. Quieting the stress response preserves both ovarian function and progesterone precursor availability.

The Supplement Stack

I use a range of supplements to target a specific mechanism in the chain.

• Myo-inositol (2g twice daily, often paired with folic acid): Acts as a second messenger in FSH signalling — sensitising follicles to FSH stimulation and reducing the FSH surges that drive chaotic hormone production. Also mimics insulin’s intracellular pathways in ovarian tissue, lowering the insulin environment within follicular fluid. Crosses the blood-brain barrier to support serotonin receptor sensitivity [Angeloni A, Piombarolo A, Bizzarri M, et al. Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review. Nutrients. 2023;15(8):1875. doi:10.3390/nu15081875].
• CoQ10/Ubiquinol (100–200mg daily): The ovaries have the highest mitochondrial density of any organ in the body. Mitochondrial function declines with age, generating free radicals that damage follicles. CoQ10 neutralises these radicals, preserving mitochondrial efficiency and slowing the follicle breakdown that leaves collagen-filling gaps in the ovarian cortex.
• NAC — N-Acetyl Cysteine (600–1200mg daily, on an empty stomach): The primary precursor to glutathione — the body’s master antioxidant. NAC reduces pro-inflammatory cytokines in the pelvic environment, protects granulosa cell survival, and dampens the baseline inflammation that activates myofibroblasts and drives fibrosis.
• Resveratrol (100–250mg daily): Activates the SIRT1 longevity pathway, which is depleted in ageing ovarian tissue. Supports cellular architecture, preserves follicle reserve integrity, and slows the tissue stiffening process.
• Magnesium glycinate (200–400mg in the evening): The foundational calming mineral. Lowers insulin resistance. Stabilises cortisol output. Improves sleep architecture through GABA-A adjacent mechanisms. Shields ovarian tissue from the structural damage driven by chronic cortisol exposure. In the context of flooding periods, magnesium depletion directly impairs smooth muscle contraction and uterine vessel clamping.
• Omega-3 EPA/DHA (2000–3000mg combined daily): Improves cell membrane fluidity throughout the body, including ovarian follicle membranes. Research indicates omega-3 supplementation can directly lower circulating FSH. Blocks the lipid-accumulation pathways that drive tissue stiffening.
• Vitamin D (dose based on serum 25-hydroxyvitamin D testing): Acts as a natural molecular brake on the TGF-β pathway — the principal fibrosis driver. Prevents fibroblast-to-myofibroblast conversion and has significant immune-regulatory effects in the ovarian environment [Gu M et al. J Ovarian Res. 2024; doi:10.1186/s13048-024-01448-7].
• Melatonin (1–3mg before bed): Found in the highest concentrations in follicular fluid — higher than in blood. Produced within egg mitochondria as a powerful local antioxidant, it clears the free radicals generated by ageing mitochondria, slows follicular tissue failure, and supports sleep architecture through multiple pathways.

Supporting Oestrogen Clearance

Liver: Cruciferous vegetables — broccoli, cauliflower, Brussels sprouts — contain DIM (diindolylmethane) and I3C (indole-3-carbinol) which support Phase II oestrogen detoxification pathways. Adequate B12 and folate are essential for methylation, the biochemical process through which used oestrogen is deactivated for excretion. Alcohol should be minimised; it significantly impairs hepatic oestrogen processing.

Gut: Address dysbiosis directly — probiotic support, prebiotic fibre, and where indicated, targeted interventions to reduce beta-glucuronidase-producing bacteria. Ensure regular bowel transit; constipation is not a minor inconvenience in this context, it is a factor in oestrogen recirculation. The estrobolome is not a metaphor — it is an active regulator of circulating oestrogen levels.

Xenoestrogens: Switch food storage to glass and stainless steel. Review cosmetics and personal care products. Choose organic produce for high-pesticide foods. These changes accumulate meaningfully over time.

Why Standard HRT Often Fails — or Makes Things Worse — in This Phase

This is a pattern Sandra sees repeatedly, and it requires a clear explanation: early perimenopause is an oestrogen-dominant picture, not an oestrogen-deficient one. Standard HRT is designed for the invented oestrogen deficiency. Applied to oestrogen dominance, it frequently worsens the underlying problem.

1. Oestrogen dominance mismatch.
Standard HRT adds exogenous oestrogen to a system that is already producing too much, or too much relative to progesterone. The result: receptor over-saturation. Breast tenderness worsens. Bloating worsens. Migraines become more frequent. Irritability deepens. Women are told to “give it time” — but the fundamental mismatch is not timing, it is the hormonal direction of the intervention.

2. Additive versus suppressive dosing.
Low-dose HRT top-ups are simply overridden by the body’s own wild hormone swings, which can produce oestrogen spikes far exceeding what any transdermal gel delivers. The dose is not high enough to control the ovaries’ erratic output. The only way to fully override endogenous production would be suppressive dosing — essentially putting the ovaries to sleep, as a combined oral contraceptive does. That is a different clinical conversation, not standard HRT.

3. Progestogen intolerance.
Synthetic progestogens (the form used in most standard HRT preparations) are not the same as progesterone. They do not convert to allopregnanolone. Many women experience severe PMS-like side effects from progestogens — flat mood, fatigue, anxiety, bloating — and assume HRT is not working. They are reacting to the progestogen component. This is a widely underrecognised cause of HRT dissatisfaction.

4. Poor transdermal absorption.
Skin absorption of oestrogen and progesterone through patches and gels varies enormously between individuals. Some women absorb very little. Standard dosing guidelines are population averages. Without testing serum levels after application, a woman can appear to be “on HRT” while receiving clinically negligible amounts — leaving symptoms completely unaddressed.

My approach addresses root causes first: dampen the insulin-oestrogen loop, support liver clearance, restore gut health, reduce xenoestrogen exposure, protect progesterone from the cortisol steal, and slow ovarian fibrosis. These are the actual drivers. Adding hormones on top of unaddressed root causes rarely resolves the picture.

Rachel’s Story

Rachel was 44 when she first came to Sandra. She was still cycling, but her periods had become catastrophic — flooding, clots, bleeding for 8–10 days. In the two weeks before her period, she was anxious, barely recognisable to herself — snapping at her children, unable to sleep, gripped by dread. Then, for two weeks, she felt almost normal. Her breasts were so tender in the second half of her cycle she couldn’t sleep on her side.

Her GP had offered HRT. She tried it for three months. It made everything worse — more bloating, more breast pain, migraines that had previously been manageable became severe. She was told her bloods were normal and offered antidepressants.

My assessment identified early perimenopause with oestrogen dominance as the likely driver. We ran a targeted functional panel: ferritin came back at 9 (critically depleted from months of flooding), B12 borderline, Vitamin D low, fasting insulin elevated, cortisol pattern disrupted — flattened morning output, elevated evening. Classic stress-axis dysregulation in the context of early perimenopause.

The protocol addressed each lever: blood sugar management and a reduced refined carbohydrate approach to lower the insulin-oestrogen amplification loop; liver support through cruciferous vegetables, B vitamins, and reduced alcohol; gut work to support the estrobolome; a B vitamin complex to address the B12 and B6 deficiencies; magnesium glycinate in the evening for sleep, cortisol stabilisation, and uterine muscle function; myo-inositol to support FSH signalling.

Within three cycles: the flooding had significantly reduced. The luteal anxiety window narrowed from two weeks to a few days at most. The breast tenderness was almost gone.

“I felt like I was going mad. The HRT made everything worse and nobody could explain why. Understanding the root cause changed everything — I finally felt like I had a map.”

(Rachel is a composite case. Details are representative of clinical patterns, not a single individual.)

The protocol addresses all the drivers simultaneously — because they are all connected.
Lower insulin. Support liver oestrogen clearance. Restore gut health. Replenish depleted nutrients. Quiet the cortisol burden that suppresses ovulation via the hypothalamus. Slow ovarian fibrosis. The full approach is outlined on The Progesterone Shift →

Is The Progesterone Shift Driving Your Symptoms?

If what you’ve read here feels like your story — the flooding, the luteal anxiety, the HRT that made things worse, the normal blood tests — this is the work Sandra does.

Book a consultation with Sandra →

References

1. Gu M, Yu Y, Wang Y. Ovarian fibrosis: molecular mechanisms and potential therapeutic targets. Journal of Ovarian Research. 2024;17:131. doi:10.1186/s13048-024-01448-7
2. Edepli BG, Yaba A. Molecular mechanisms of ovarian fibrosis. Molecular Human Reproduction. 2025; doi:10.1093/molehr/gaaf058
3. Johnson BW, Duncan F, Kelsh J, et al. Fibroinflammatory Signatures Increase with Age in the Human Ovary and Follicular Fluid. International Journal of Molecular Sciences. 2021;22(9):4902. doi:10.3390/ijms22094902
4. Vanderhyden B, Cook D, Landry DA, et al. Metformin prevents age-associated ovarian fibrosis by modulating the immune landscape in female mice. Science Advances. 2022;8(38):eabq1475. doi:10.1126/sciadv.abq1475
5. Hantsoo L, Epperson CN. Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiology of Stress. 2020;12:100213. doi:10.1016/j.ynstr.2020.100213
6. McEvoy K, Osborne LM. Allopregnanolone and reproductive psychiatry: an overview. International Review of Psychiatry. 2019;31(3):237–44. doi:10.1080/09540261.2018.1553775
7. Zorumski CF, Covey DF, Mennerick S, Paul S. Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond. Neurobiology of Stress. 2019;11:100196. doi:10.1016/j.ynstr.2019.100196
8. Wirth M. Beyond the HPA Axis: Progesterone-Derived Neuroactive Steroids in Human Stress and Emotion. Frontiers in Endocrinology. 2011;2:19. doi:10.3389/fendo.2011.00019
9. Li H, Lim L, Roberts LR, Redinbo M, Ervin S, Mani S, Liang X. Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome. Journal of Biological Chemistry. 2019;294(49):18586–99. doi:10.1074/jbc.RA119.010950
10. Ma JX, Zhao L, Kang M, et al. Gut microbial beta-glucuronidase: a vital regulator in female estrogen metabolism. Gut Microbes. 2023;15(1):2236749. doi:10.1080/19490976.2023.2236749
11. Dupont J, Scaramuzzi R. Insulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycle. Biochemical Journal. 2016;473(11):1483–501. doi:10.1042/BCJ20160124
12. Angeloni A, Piombarolo A, Bizzarri M, et al. Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review. Nutrients. 2023;15(8):1875. doi:10.3390/nu15081875
13. Kajdy A, Rogowski A, Dmoch-Gajzlerska E, et al. Progesterone and Its Metabolites Play a Beneficial Role in Affect Regulation in the Female Brain. Pharmaceuticals. 2023;16(4):520. doi:10.3390/ph16040520